BioNTech AG to Present at Cantor Fitzgerald Healthcare Conference

Mainz, Germany, September 19, 2017 – BioNTech AG, a fully integrated…

BioNTech announces positive results of an international reproducibility study with MammaTyper®

International multicenter study in ten pathology laboratories…

EU-funded consortium led by BioNTech and Immatics announces completion of regular study treatment in the GAPVAC-101 trial

Mainz/Tuebingen, Germany, 24th March 2017: BioNTech AG and Immatics…

BioNTech to present interim Phase I/II date for mRNA vaccine at AACR

Mainz, Germany, March 7, 2017 - BioNTech AG, a fully-integrated…

BioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference

Mainz, Germany, February 22, 2017: BioNTech AG, a fully integrated…

MammaTyper® enables more precise prediction of the response to neoadjuvent chemotherapy compared to manual or digitalized IHC

First comparison of a biomarker analysis by RT-qPCR (MammaTyper®)…

BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017

Mainz, Germany, 22nd December 2016: BioNTech AG, a fully integrated…

BioNTech to enter into worldwide strategic collaboration with Genentech to develop individualized mRNA cancer therapies

Mainz, Germany, September 21, 2016 - BioNTech AG, a fully integrated…

Chinese FDA Grants MammaTyper® Innovative Product Status for Expedited Approval

Mainz, Germany and Deqing, China, August 19, 2016 — BioNTech…

Study confirms analytical precision of MammaTyper® in molecular breast cancer typing

Mainz, Germany, July 12, 2016:  BioNTech Diagnostics GmbH announces…